尤瑞克林治疗46例不同时间窗急性脑梗死的临床观察

The clinical investigation of Urinary Kallidinogenas on the 46 different time window patients with acute cerebral infarction

目的总结尤瑞克林治疗4.5h以内和4.5～48h不同时间窗急性脑梗死的临床疗效和安全性。方法以2011年1月至2012年4月间收治的46例住院的急性脑梗死患者为研究对象(观察组),给予尤瑞克林0.15PNA.d-1,连续静脉点滴7d。其中4.5h以内用药组17例、4.5～48h用药组29例,同时选取对照组30例。结果 4.5h内用药组和4.5～48h用药组在尤瑞克林治疗后7d,临床功能改善程度和NIHSS评分变化均明显优于对照组(P<0.05),全部患者无出血及过敏反应发生。结论尤瑞克林用于治疗4.5h以内和4.5～48h急性脑梗死均安全有效,但4.5h以内临床疗效更好。

Objective To study the clinical effect of Urinary Kallidinogenas on the different time window patients(≤ 4.5h and 4.5～48h) with acute cerebral infarction.Methods From JAN.2011 to APR.2012,total 46 patients with acute cerebral infarction were cured by Urinary Kallidinogenas,and 30 subjects were selected in control group.Results The clinical function improvement degree and NIHSS scores of treatment group(≤ 4.5h and 4.5～48h) were significantly better than control group after Urinary Kallidinogenas treatment 7 days(P<0.05).There were no hemorrhage and allergy among all subjects.Conclusions The Urinary Kallidinogenas therapy is safe and effective for acute cerebral infarction patients of different time window(≤4.5h and 4.5～48h) but the clinical effect was better for the patients(≤ 4.5h) with alteplase thrombolytic therapy